Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465268 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT02465268 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 175 participants.
The verdict
NCT02465268, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.
Interventions
- DRUG Saline
- BIOLOGICAL pp65-shLAMP DC with GM-CSF
- BIOLOGICAL unpulsed PBMC and saline
- DRUG Td
- BIOLOGICAL pp65-flLAMP DC with GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2016-08-09 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465268
The ClinicalTrials.gov registry entry for NCT02465268 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Saline is the first listed.
NCT02465268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465268 about?
NCT02465268 is a clinical study titled "Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme". The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.
What is the current status of trial NCT02465268?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2016-08-09. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT02465268?
The interventions under investigation include: Saline (DRUG), pp65-shLAMP DC with GM-CSF (BIOLOGICAL), unpulsed PBMC and saline (BIOLOGICAL), Td (DRUG), pp65-flLAMP DC with GM-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT02465268?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.